Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 13/20 | 0.40 |
| ▸ | CA2 | P00918 | 13/20 | 0.40 |
| ▸ | EYA2 | O00167 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MVD | P53602 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Creatine SCHEMBL27979093 | 1.00 | NOS3 (0.46) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL30063981 | 1.00 | — | — | |
| Creatine SCHEMBL21567 | 1.00 | — | — | |
| Creatine SCHEMBL21404054 | 0.98 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL5326455 | 0.98 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL1241423 | 0.98 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL675799 | 0.98 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL21810557 | 0.98 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL20497169 | 0.98 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL4269042 | 0.98 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001004128-A1 | BIOAVAILABLE CHELATES OF CREATINE AND ESSENTIAL METALS | ALBION INTERNATIONAL, INC. (US) | 2001-01-18 | — | — | WO | claimed |
| WO-2024058984-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3771709-B1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | FARMINGTON PHARMA DEV (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11407722-B2 | Creatine prodrugs, compositions and methods of use thereof | Farmington Pharma Development (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3771709-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | Farmington Pharma Development (US) | 2021-02-03 | — | — | EP | disclosed |
| EP-3237391-B1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | FARMINGTON PHARMA DEV (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-3694646-A1 | A STREAMLINED METHOD FOR ANALYTICAL VALIDATION OF BIOCHEMICALS DETECTED USING AN UNTARGETED MASS-SPECTROMETRY PLATFORM | Metabolon, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3684350-A1 | AMINO ACIDS COMPOSITIONS FOR THE TREATMENT OF NEURONAL INJURY | Axcella Health Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-3681521-A1 | METABOLOMIC REVISION OF MAMMALIAN INFANTS | Evolve Biosystems Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190337909-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | Farmington Pharma Development | 2019-11-07 | — | — | US | disclosed |
| WO-2006122552-A1 | METHOD OF STABILISING OR REACTIVATING A CREATININE SENSOR WITH A SOLUTION OF A DIVALENT MANGANESE ION | RADIOMETER MEDICAL APS (DK) | 2006-11-23 | — | — | WO | disclosed |
| EP-1723413-A1 | TEST ELEMENT WITH A CAPILLARY FOR TRANSPORT OF A LIQUID SAMPLE | Roche Diagnostics GmbH (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006026458-A2 | COMPOSITIONS AND METHODS FOR ACTIVATING PROTEIN SYNTHESIS AND DEACTIVATING CATABOLIC PROCESSES IN SKELETAL MUSCLE | MTOR FORMULATIONS LTD. (CA) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005080978-A1 | TEST ELEMENT WITH A CAPILLARY FOR TRANSPORT OF A LIQUID SAMPLE | ROCHE DIAGNOSTICS GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
| CN-1187618-C | Reagent box for fast detecting methyl amphetamine and its preparation process | KAICHUANG BIOTECHNOLOGY CO LTD (CN) | 2005-02-02 | — | — | CN | disclosed |
| WO-2004071406-A2 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2004-08-26 | — | — | WO | disclosed |
| CN-1410770-A | Reagent box for fast detecting methyl amphetamine and its preparation process | KAICHUANG BIOTECHNOLOGY CO LTD (CN) | 2003-04-16 | — | — | CN | disclosed |
| US-5968544-A | ACIDIC YOGURT | THE HOWARD FOUNDATION (GB) | 1999-10-19 | — | — | US | disclosed |
| US-5496716-A | FOR USE AS CALIBRATOR OR CONTROL REFERENCE IN IMMUNOASSAY; CONTAINS ONE ENZYME SUBSTRATE OR ANALOG AND ENZYME PRODUCT OR ANALOG COMBINED WITH ENZYME | ABBOTT LABORATORIES (US) | 1996-03-05 | — | — | US | disclosed |
| WO-1991005063-A1 | HALOPEROXIDASE ACID OPTIMUM CHEMILUMINESCENCE ASSAY SYSTEM | EXOXEMIS, INC. (US) | 1991-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337909-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | CKMT1A; CKMT1B, SLC2A1, SLC29A2 | NOS3 2303/4885NOS1 2486/4885NOS2 2280/4885 |
| US-11407722-B2 | Creatine prodrugs, compositions and methods of use thereof | CKMT1A; CKMT1B, SLC2A1, SLC29A2 | NOS3 2303/4885NOS1 2486/4885NOS2 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.